A detailed history of Valeo Financial Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Valeo Financial Advisors, LLC holds 5,885 shares of VRTX stock, worth $2.72 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
5,885
Previous 6,338 7.15%
Holding current value
$2.72 Million
Previous $2.65 Million 4.11%
% of portfolio
0.08%
Previous 0.08%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 10, 2024

SELL
$392.81 - $485.53 $177,942 - $219,945
-453 Reduced 7.15%
5,885 $2.76 Million
Q1 2024

Apr 25, 2024

SELL
$407.69 - $446.08 $166,745 - $182,446
-409 Reduced 6.06%
6,338 $2.65 Million
Q1 2024

Apr 19, 2024

BUY
$407.69 - $446.08 $466,397 - $510,315
1,144 Added 20.42%
6,747 $2.82 Million
Q4 2023

Jan 29, 2024

BUY
$343.0 - $410.68 $430,808 - $515,814
1,256 Added 28.89%
5,603 $2.28 Million
Q3 2023

Oct 19, 2023

BUY
$338.18 - $362.46 $12,174 - $13,048
36 Added 0.84%
4,347 $1.51 Million
Q2 2023

Jul 14, 2023

SELL
$314.42 - $351.91 $324,167 - $362,819
-1,031 Reduced 19.3%
4,311 $1.52 Million
Q1 2023

Apr 17, 2023

BUY
$283.23 - $323.1 $187,498 - $213,892
662 Added 14.15%
5,342 $1.68 Million
Q4 2022

Feb 09, 2023

SELL
$285.76 - $321.48 $168,598 - $189,673
-590 Reduced 11.2%
4,680 $1.35 Million
Q3 2022

Oct 31, 2022

BUY
$273.83 - $305.53 $276,294 - $308,279
1,009 Added 23.68%
5,270 $1.53 Million
Q2 2022

Aug 03, 2022

BUY
$234.96 - $292.55 $224,621 - $279,677
956 Added 28.93%
4,261 $1.2 Million
Q1 2022

Apr 28, 2022

BUY
$221.42 - $260.97 $239,133 - $281,847
1,080 Added 48.54%
3,305 $863,000
Q4 2021

Jan 07, 2022

BUY
$177.01 - $223.45 $393,847 - $497,176
2,225 New
2,225 $489,000
Q2 2021

Jul 22, 2021

SELL
$187.49 - $221.1 $974,385 - $1.15 Million
-5,197 Closed
0 $0
Q1 2021

Apr 12, 2021

BUY
$207.02 - $241.31 $40,368 - $47,055
195 Added 3.9%
5,197 $1.12 Million
Q4 2020

Feb 11, 2021

BUY
$207.01 - $276.09 $950,175 - $1.27 Million
4,590 Added 1114.08%
5,002 $1.18 Million
Q3 2020

Oct 28, 2020

SELL
$255.65 - $303.1 $105,072 - $124,574
-411 Reduced 49.94%
412 $112,000
Q2 2020

Jul 20, 2020

BUY
$225.48 - $295.8 $30,439 - $39,933
135 Added 19.62%
823 $239,000
Q1 2020

Apr 13, 2020

SELL
$199.77 - $247.81 $137,641 - $170,741
-689 Reduced 50.04%
688 $170,000
Q4 2019

Jan 24, 2020

BUY
$166.71 - $223.91 $66,850 - $89,787
401 Added 41.09%
1,377 $301,000
Q3 2019

Oct 15, 2019

SELL
$166.23 - $187.09 $15,459 - $17,399
-93 Reduced 8.7%
976 $165,000
Q2 2019

Jul 10, 2019

BUY
$164.61 - $190.37 $68,642 - $79,384
417 Added 63.96%
1,069 $196,000
Q1 2019

Apr 12, 2019

SELL
$163.73 - $194.7 $4,748 - $5,646
-29 Reduced 4.26%
652 $120,000
Q4 2018

Jan 30, 2019

BUY
$151.91 - $192.21 $15,950 - $20,182
105 Added 18.23%
681 $113,000
Q3 2018

Nov 01, 2018

BUY
$167.73 - $192.74 $41,429 - $47,606
247 Added 75.08%
576 $98,000
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $42,550 - $49,628
-292 Reduced 47.02%
329 $58,000
Q1 2018

Apr 12, 2018

BUY
$151.6 - $177.13 $48,663 - $56,858
321 Added 107.0%
621 $101,000
Q4 2017

Feb 09, 2018

BUY
$137.28 - $155.55 $13,728 - $15,555
100 Added 50.0%
300 $45,000
Q3 2017

Nov 14, 2017

BUY
$148.13 - $162.24 $29,626 - $32,448
200
200 $30,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Valeo Financial Advisors, LLC Portfolio

Follow Valeo Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valeo Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Valeo Financial Advisors, LLC with notifications on news.